News | Radiation Therapy | January 29, 2016

ASTRO Hires New Director of Scientific Affairs

Position created to increase research participation and collaboration in the field of radiation oncology

January 29, 2016 — The American Society for Radiation Oncology (ASTRO) recently welcomed Judy Keen, Ph.D., as its director of scientific affairs, a position created to grow research participation and collaboration in the field of radiation oncology.

As the ASTRO lead on scientific affairs, Keen will develop and implement initiatives that promote clinical, translational and basic radiation research, with the ultimate goal of advancing both science and evidence-based patient care throughout the radiation oncology community. Efforts involved in this push to grow research participation among radiation oncologists include managing the various funding mechanisms offered by ASTRO — such as its junior faculty awards and seed grants — as well as finding and promoting opportunities from external funding agencies to share with ASTRO members, which include nearly all practicing radiation oncologists in the United States.

Keen also will spearhead efforts to develop broader collaborations within the cancer research community, thereby responding to the growing need to eradicate the silos that can impede scientific progress. Among other roles, Keen will serve as ASTRO’s primary scientific liaison to internal and external partners involved in performing and promoting biomedical research, including the ASTRO Science Council, federal agencies, other medical societies, coalitions, the biopharmaceutical industry and policymakers.

Keen brings a wealth of diverse experience conducting and managing research projects to her new position. Prior to joining ASTRO, Keen was director of research collaborations for the National Breast Cancer Coalition (NBCC), where she led scientific oversight for multiple programs.

Before NBCC, she worked at the National Cancer Institute within the National Institutes of Health (NIH), first as a health science analyst in the Office of Science Planning and Assessment, then as program director for the NIH Genotype Tissue Expression (GTEx) project within the Biorepository and Biospecimen Research Branch. The GTEx effort included curating a collection of genomic and clinical data from more than 900 donors that was designed to explore genetic variability in humans and the changes that lead to disease.

Keen also spent several years as an assistant professor in the department of medicine at the Robert Wood Johnson Medical School at the University of Medicine and Dentistry of New Jersey, where she focused on ways to improve responses to chemotherapy in breast cancer.

Keen earned her doctorate in physiology and completed her postdoctoral training in breast cancer research at Johns Hopkins University in its Schools of Public Health and Medicine, respectively. She also earned a master of science degree in biotechnology from Hopkins and a bachelor of science degree in biology from Gettysburg College in Pennsylvania.

“Judy understands the fundamental role of research and science in helping radiation oncology teams provide the best possible care to their patients, which we can see from her extensive background both conducting research and promoting scientific activities,” said Laura Thevenot, chief executive officer of ASTRO. “I welcome her expertise and look forward to leveraging ASTRO’s position as the world’s premier radiation oncology society to further advance scientific knowledge within radiation biology and oncology.”

For more information:

Related Content

Cleveland Clinic Researchers Reveal Biomarker for Guiding Prostate Cancer Treatment
News | Prostate Cancer | October 17, 2017
October 17, 2017 — Back-to-back discoveries from Cleveland Clinic demonstrate for the first time how a testosterone-r
IBA Announces First Use of Gating With Active Scanning Proton Therapy in Italy
News | Proton Therapy | October 17, 2017
October 17, 2017 — The Trento Azienda Provinciale per i Servizi Sanitari (APSS) and IBA announced the successful comp
Elekta and Brainlab Offer Streamlined Workflow for Stereotactic Radiotherapy
News | Radiation Therapy | October 16, 2017
Elekta and Brainlab have reconfirmed their alliance for the integrated use of the Elekta Versa HD linear accelerator...
National Breast Center Founder Names Top Three Innovations in Breast Cancer Treatment
News | Women's Health | October 11, 2017
In 2017, invasive breast cancer will be diagnosed in about 252,710 women and 2,470 men in the U.S. and remains the...
CyberKnife System Provides Excellent Long-Term Control of Low-Risk Prostate Cancer
News | Stereotactic Body Radiation Therapy (SBRT) | October 10, 2017
Accuray Inc. announced that data from a prospective study of 230 men with low-risk prostate cancer showed 98.4 percent...
News | Image Guided Radiation Therapy (IGRT) | October 10, 2017
Elekta announced that members of the Elekta MR-linac Consortium reported data related to the advancement of the company...
Sponsored Content | Videos | Radiation Therapy | October 09, 2017
David Beyer, M.D., chairman of the board for the American Society of Radiation Oncology (ASTRO), discusses the key th
Sponsored Content | Videos | Radiation Therapy | October 09, 2017
Benjamin Movsas, M.D., chair of the American Society for Radiation Oncology (ASTRO) Scientific Committee, explains ho
News | Brachytherapy Systems | October 05, 2017
External researchers presented new clinical data supporting the use of iCAD’s Xoft Axxent Electronic Brachytherapy (eBx...
MedLever Showcases Radiation Oncology Applications at ASTRO 2017
News | Radiation Therapy | October 05, 2017
MedLever demonstrated its flagship platform and applications that simplify clinical workflow, enable interoperability,...
Overlay Init